|Day Low/High||73.72 / 74.80|
|52 Wk Low/High||64.27 / 89.54|
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the company's liver disease research and development programs in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), hepatitis B virus (HBV) infection and hepatitis...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1489) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...
In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks HONG KONG, Oct.
Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration...
Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.
Jim Cramer takes a closer look at Total SA, Bluebird Bio, U.S. Silica Holdings, Nucor, International Paper, Nokia, Alibaba.
Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni ® (ledipasvir 90mg/sofosbuvir 400mg), Gilead's leading treatments for chronic hepatitis C virus...
Jim Cramer takes a look at General Electric, Chevron, Manitowoc, Gilead Sciences, Encore Capital Group, Tower Semiconductor, Camping World, Kinder Morgan and more.
Jim Cramer says sustained, revolutionary innovation creates new demand where it didn't exist before.
These call buyers may have expected positive, bullish news in the coming weeks, on the belief that the pipeline for GILD is broad with a multitude of opportunities to serve as catalysts.
Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision's proprietary genome...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with...
Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint...
Gilead Sciences, Inc. (NASDAQ: GILD) and Trianni, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead's senior leadership team.
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta ® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell...
Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients.
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.